The latest from Jan Manarite of PCRI about the getting early access to Abiraterone for men with advanced prostate cancer and who have failed chemotherapy: Abiraterone expanded Access Trial Site Contact Info – 2/7/11 (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic 3. no brain [...]
The House Appropriations Committee released revised subcommittee allocations yesterday for FY 2011. The new FY 2011 Labor-HHS-Education Subcommittee allocation is $157.02 billion, which is nearly $6.6 billion (4 percent) below the subcommittee’s FY10 allocation. The House is scheduled to vote on a FY11 appropriations bill during the week of February 14. Specific funding levels and [...]
A recent study conducted at the Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA by the Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA, evaluated the efficacy of the timely use of zoledronic acid (ZA) on clinical outcomes and health care utilization in men with bone-metastatic prostate [...]
There are two different dosage levels used for the administration of Ketoconazole (Keto), a commonly used 2nd line hormone deprivation drug used after the failure of the traditional drugs (Lupron, Zoladex etc.). Low dosage keto involves taking 200 mg three times a day (600 mg per day), while high dose keto uses 400 three times [...]
Recently, I received two separate questions about both low dose ketoconazole (LDK) and high dose ketoconacole (HDK). For both of these men with castrate resistant advanced prostate cancer, their PSA scores continued to rise, despite their using keto. Even when taken properly, not all men experience a positive effect from the drug (a decline in [...]